ATX.AX

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2027	$0	—	$-0.02	$-0.02–$-0.02	—	1
2028	$10M	—	$-0.01	$-0.01–$-0.01	—	1
2029	$10M	+0.0%	$-0.01	$-0.01–$-0.01	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

DCF fair valuemodel estimate

Intrinsic value

$0.07

Price

$0.12

Implied downside

-46%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
ATX.AXAmplia Therapeutics Limited	$0.12	+0.00%	$62M	—
BMT.AXBeamtree Holdings Limited	$0.10	+0.00%	$31M	—
CYC.AXCyclopharm Limited	$0.50	-7.41%	$63M	—
CYP.AXCynata Therapeutics Limited	$0.01	+0.00%	$3M	—
GSS.AXGenetic Signatures Limited	$0.07

Amplia Therapeutics Limited

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

www.ampliatx.com

Employees: 8
IPO / List date: Dec 19, 2013
HQ: AU

Held by traders on TradeandTell

No one on the platform currently holds ATX.AX.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in ATX.AX as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded ATX.AX yet.